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Abstract
We conducted a novel pilot randomized controlled trial of the Treatment Ambassador Program (TAP), an 8-session, peer-
based, behavioral intervention for people with HIV (PWH) in South Africa not on antiretroviral therapy (ART). PWH (43 
intervention, 41 controls) completed baseline, 3- and 6-month assessments. TAP was highly feasible (90% completion), with 
peer counselors demonstrating good intervention fidelity. Post-intervention interviews showed high acceptability of TAP 
and counselors, who supported autonomy, assisted with clinical navigation, and provided psychosocial support. Intention-
to-treat analyses indicated increased ART initiation by 3 months in the intervention vs. control arm (12.2% [5/41] vs. 2.3% 
[1/43], Fisher exact p-value = 0.105; Cohen’s h = 0.41). Among those previously on ART (off for > 6 months), 33.3% initiated 
ART by 3 months in the intervention vs. 14.3% in the control arm (Cohen’s h = 0.45). Results suggest that TAP was highly 
acceptable and feasible among PWH not on ART.
Keywords Engagement in care · South Africa · ART initiation · Motivational interviewing · Peer-based intervention · 
Behavioral intervention · Differentiated service delivery
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Introduction
South Africa currently provides treatment for nearly 60% 
of the 7.9 million people with HIV (PWH) in the country. 
While this is over a two-fold increase in the past decade 
[1], it is still far from achieving UNAIDS 90–90–90 targets 
[2]. Significant attrition from the care cascade has been 
documented consistently throughout the region, despite 
sweeping changes made to increase access to and avail-
ability of antiretroviral therapy (ART) [3–7]. A recent pro-
spective cohort study of 500 PWH presenting for testing in 
Soweto and Gugulethu townships adds to these data, show-
ing that 62% of treatment-eligible PWH initiated ART, but 
only 25% had evidence of an undetectable HIV-1 plasma 
RNA (< 50 copies/ml) within 9 months of testing [8, 9].
Prior research has shown PWH encounter individual, 
social, and structural barriers to initiating care, such as 
fear of side effects, HIV-associated stigma, and long clinic 
waiting times [10]. For those who delay or decline treat-
ment, the perceived risks of disclosing one’s status and 
experiencing HIV-associated stigma may outweigh the 
life-saving benefits of ART [11]. Conversely, those who 
start treatment and achieve viral suppression do so through 
a combination of adaptive coping and support from key 
partners. These findings are consistent with other studies 
showing that PWH who have non-judgmental, noncon-
frontational support are more likely to be engaged in care 
[12, 13].
While prior research has focused on how to better 
engage individuals who fail to initiate ART, few studies 
have developed interventions targeting individuals who 
were previously on ART but discontinued treatment [7, 
10]. Differentiated service delivery models, client-cen-
tered approaches that simplify and adapt HIV services to 
reflect the preferences, expectations, and needs of indi-
vidual PWH, while reducing unnecessary burdens on the 
healthcare system, are critical in engaging this population 
in care [8, 14, 15]. Behavioral research can inform the 
feasibility and acceptability of differentiated care models 
for optimizing ART initiation and adherence. In particu-
lar, research focused on increasing resilience, or individu-
als’ capacity to overcome adversity and stress to achieve 
health and well-being [16–18], may be especially helpful 
for identifying modifiable strength-based factors that can 
promote healthy outcomes [11, 19, 20].
Interventions promoting adaptive coping may be associ-
ated with acceptance of a new HIV diagnosis by fostering 
problem solving and emotional expression, while mitigat-
ing the perceived risk associated with starting treatment 
[7, 21]. In addition, enhancing social support, including 
comfort and/or assistance from others, has been shown to 
be associated with better HIV-related health symptoms 
among PWH, possibly because it buffers people from 
the negative effects of stressors on physical health [19, 
20]. For this reason, peer-delivered interventions may be 
successful in improving engagement in care for PWH by 
increasing levels of social support as well as providing 
patients with information on how to best navigate HIV-
services [12, 22–28].
In this study, we developed and tested a new intervention, 
called the “Treatment Ambassador Program (TAP),” a client-
focused, peer-based differentiated care strategy for address-
ing individual, social, and structural level barriers to ART 
initiation, in order to promote early and enduring treatment 
uptake by PWH [29–31]. Given its focus on reducing indi-
vidual barriers to starting ART, promoting social support, 
and enhancing linkages to the healthcare system, we hypoth-
esized that the Treatment Ambassador Program would be 
highly acceptable and feasible among PWH who faced chal-
lenges initiating or staying on ART in South Africa [32, 33].
Methods
Study Design
The study was a pilot randomized controlled trial of an 
intervention targeting PWH in Gugulethu Township, South 
Africa. We assessed acceptability and feasibility, along with 
fidelity to the intervention by peer interventionists, called 
“Treatment Ambassadors.” Eighty-four participants com-
pleted structured surveys at baseline; follow-up assessments 
occurred at three and 6-months post-baseline. Participants 
were randomly assigned at a 1:1 ratio to intervention (n = 41) 
or control (n = 43) arms at baseline. We also conducted an 
evaluation of the different intervention components and their 
implementation using semi-structured exit interviews with 
30 randomly selected participants (25 from the interven-
tion arm and 5 from the control arm) upon completion of 
the intervention [34]. All study visits (for intervention and 
assessment sessions) took place in a neutral non-clinical 
space (e.g., a church or community center) that was con-
venient for participants.
Description of the Treatment Ambassador Program
The Treatment Ambassador Program was iteratively devel-
oped in partnership with a Community Advisory Board, a 
group of key stakeholders in the Gugulethu community, who 
provided crucial contextual expertise and guidance in the 
development of the intervention. Specifically, the research 
team met with the Community Advisory Board three to four 
times per year, beginning in the pre-pilot phase, and through 
the end of the study to solicit feedback, and provide progress 
reports. Core intervention components included one-on-one 
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client-centered counseling sessions and patient navigation. 
The intervention development was based on prior research 
[7, 35, 36] and findings from a large systematic review 
focused on understanding why PWH delayed or discon-
tinued treatment in low- and middle-income countries [6]. 
Building on the Theory of Triadic Influence (TTI) [37], this 
intervention was designed to address individual-, social-, 
and structural-level barriers to ART initiation (see Fig. 1). 
TAP was hypothesized to work through several mechanisms 
and levels as framed by the TTI: (1) individual-level factors, 
including attitudes and beliefs about treatment, by building 
the knowledge base and trust of treatment for participants, 
while promoting self-efficacy and effective coping strategies; 
(2) social-level factors through social interactive processes 
that address HIV-related stigma and the need for disclosure; 
and (3) structural-level factors through facilitating engage-
ment with clinic providers.
The intervention was tailored for the South African con-
text using content and strategies from Motivational Inter-
viewing (MI)-enhanced interventions that were developed 
and tested in the U.S [38–40]. As shown in Table 1, the full 
intervention consisted of eight sessions over 8–14 weeks for 
PWH who had not initiated treatment within 6 months of 
testing or had previously initiated ART, but been off treat-
ment for over 6 months. MI strategies were used to cre-
ate collaborative, goal-oriented communication focused 
on enhancing intrinsic motivation for behavior change by 
helping individuals to identify discrepancies between their 
stated goals and values, and current behavior [41]. Treat-
ment Ambassadors helped clients to develop problem-solv-
ing skills to overcome key individual- and social-level barri-
ers. Interventions using MI have demonstrated acceptability, 
feasibility, and fidelity in research in South Africa [42, 43].
Two Treatment Ambassadors were identified by study 
staff from a group of PWH previously selected from 
among the 2500 PWH in care at Gugulethu Community 
Health Centers to be trained as clinic counselors [44]. The 
Treatment Ambassadors underwent two rounds of three full 
days of intensive training over 6 months in MI techniques 
and TAP intervention content and structure. Consistent with 
the client-centered counseling approach, TAP counselors 
tailored session content to individual participants’ needs, 
focusing on improving treatment knowledge, promoting self-
efficacy and coping skills, and supporting perceptions of 
treatment benefits. Treatment Ambassadors conveyed sto-
ries about their own experiences with these issues to partici-
pants, in order to act as role models for ART initiation. Each 
session involved goal setting and review of the participant’s 
personal treatment plan. Treatment Ambassadors offered to 
accompany participants to their preferred treatment center 
and served as a liaison with healthcare providers. They also 
provided information about how to link to services and 
encouragement to link to other services (e.g., substance 
use/mental health), as well as practical tips for navigating 
through clinic, including reviewing a detailed map of the 
steps required to initiate care in a standard public facility.
Participants
Participants (n = 84) were recruited between January and 
December 2017 in Gugulethu using a community-based 
hybrid approach comprised of targeted sampling in com-
munity-based organization and peer-to-peer recruitment 
through snowball sampling in Gugulethu township, and dis-
tributing fliers in the community describing the study with 
contact information provided. The study protocol and data 
collection instruments were approved by Human Subjects 
Committees at Partners Healthcare and the University of 
Cape Town Human Research Ethics Committee. All partici-
pants provided written informed consent. Study data were 
collected and managed using a secure, web-based, Research 
Electronic Data Capture (REDCap) tool [45]. The study was 
registered with Clinicaltrials.gov (NCT03099707). This 
study was designed as a feasibility and acceptability trial, 
Fig. 1  Conceptual model of 
Treatment Ambassador Program
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Table 1  Psycho-social components of the Treatment Ambassador Program
*Importance and confidence rulers are used as a tool to evaluate the importance an individual assigns to a given task (e.g., “On a scale of 0–10, 
ranging from not at all important to extremely important, how important is it for you to start ARVs this week?”) and the confidence they have to 
execute it (“e.g., On a scale of 0–10, ranging from not at all confident to extremely confident, how confident are you that you could start ARVs 
this week?”)
Sessions Focus and goals Content description
Session 1:
Welcome session
Focus: Building rapport and understanding of 
participant
Goal: Elicit participant’s beliefs and concerns 
about ART and treatment
Treatment Ambassador (TA) introduces self, 
explains study highlighting autonomy and sup-
portive approach
TA elicits participant’s beliefs about ART and treat-
ment and why s/he has chosen not to take ART 
With permission, TA offers information—address 
knowledge deficits or misconceptions
TA reflects participant’s reasons against/for taking 
ART and asks for thoughts
TA offers educational materials for participant to 
review/consider before next visit
Session 2:
Enhancing motivation and confidence
Focus: Enhancing motivation and confidence
Goal: Elicit participant’s treatment readiness
TA reviews participant’s thoughts about last session
TA evaluates ART readiness
TA explores participant’s beliefs about importance 
of taking ART using Importance Ruler*
TA explores participant’s confidence in their ability 
to take ART using Confidence Ruler*
TA explores link between not taking/taking ART 
and participants values using Values Clarification 
Card
TA/Participant develop a written action plan for 
one health-related goal (e.g., reduce alcohol use, 
disclosure, start ART)
TA provides summary of session and asks for 
thoughts
Sessions 3–8:
Supporting motivation, confidence, 
and skills
For each session, participant selects 
most relevant topic from list
Focus: Supporting motivation, confidence, and 
skills to address common barriers
Goals: Enhance positive attitudes, increase skills 
and support to address barriers with the goal of 
increasing treatment readiness
TA reviews participant’s thoughts about last session 
and evaluate ART-readiness
TA re-explores participant’s beliefs about impor-
tance of and confidence for taking ART using 
rulers
Participant selects session content from options 
below:
1. Addressing barriers: Elicit barriers to starting 
ART (e.g., anticipated stigma, social isolation, 
disclosure, structural barriers) and identify pos-
sible solutions
2. Personal support and disclosure: Identify people 
who can provide support and encourage disclo-
sure; role plays
3. Dealing with stigma: Elicit thoughts/worries and 
experiences, highlight external and internalized 
stigma, explore link to health/goals and coping 
strategies
4. Steps to take to start treatment: Explore why 
participant originally got tested, their awareness of 
steps necessary to start ART, interest in accompa-
niment
5. Addressing concerns about side-effects: Elicit 
concerns about treatment side-effects, with 
permission offer information and develop plan to 
address concerns
TA/Participant develop a written action plan for one 
health-related goal
TA provides summary of session and asks for 
thoughts
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rather than an effectiveness trial. As such, the sample size 
was not determined by power analysis to detect an effect 
size. Rather, the sample size was the largest that was feasible 
in the context of a small study of a novel intervention.
Eligibility Criteria
Inclusion criteria included people who: (1) were living with 
HIV; (2) were of 18 years of age or older; (3) had not initi-
ated ART within 6 months of learning their status or were off 
treatment for at least 6 months; (4) lived within 60 km of the 
testing center; and (5) were English- or isiXhosa-speaking. 
All people living with HIV were eligible for treatment under 
current South African guidelines, including peer-based treat-
ment preparedness sessions [46]. Participants were excluded 
if they were unable to provide informed consent, if they 
had been on ART within the last 6 months, or if they were 
women who reported current pregnancy at the time of con-
sent (since they qualified for intensive adherence support 
under current South African guidelines). ART laboratory 
data were obtained from the South African National Health 
Laboratory Service (NHLS) database [47–49]. Research-
ers screened 133 potential participants. Of these, 26 did not 
meet enrollment criteria due to an inability to sign informed 
consent (one individual) or recent ART use within the last 
3 months (25 individuals). An additional 23 were withdrawn 
by the Principal Investigator due to not meeting inclusion 
criteria, with three individuals ultimately found to be HIV-
negative, and 20 others appeared to be actively or recently 
on treatment based on data from NHLS (Fig. 2). Ultimately, 
84 participants were successfully enrolled.
Randomization
Participants were randomized by the study’s principal stat-
istician in a 1:1 ratio to the intervention or control arm after 
the baseline assessment was completed. Those in the control 
arm received no intervention, beyond engagement with study 
staff for the assessments at designated times. All participants 
had access to free comprehensive HIV care and services in 
community-based settings. Field staff worked with the prin-
cipal statistician to develop a randomization assignment, and 
assignments were stored in a password-protected file only 
available to the principal statistician. Staff and participants 
were not blind to intervention arm assignment, however, 
researchers were blinded during consent and the baseline 
survey, prior to randomization, so that the baseline measures 
were not biased by foreknowledge of conditions. In addition, 
team members assessing clinical outcomes in NHLS were 
blinded to the study arms of the participants during data col-
lection. Of the 84 participants enrolled, 43 were allocated to 




Eligible individuals provided signed informed consent for 
study participation and accessing NHLS data. They partici-
pated in structured, 60-min baseline and follow-up surveys 
conducted in person with a bilingual (English and isiXhosa) 
research assistant. Baseline and follow-up surveys used the 
same measures; follow-up assessments were conducted at 
Time 2 (T2; 3 months post-intervention, focused mainly on 
the past 3 months) and Time 3 (T3; 6 months post-inter-
vention, focused mainly on the past 6 months). Participants 
received Rand 100 (roughly $8 U.S.) for each baseline and 
follow-up assessment for their time and fare for local public 
transportation, and a bonus of Rand 200 (roughly an addi-
tional $16 U.S.) for completing all three surveys. Partici-
pants in the intervention arm received Rand 20 (roughly 
$1.50 U.S.) for each session to cover transportation to and 
from the venue.
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NHLS Data
We assessed ART initiation within 3 months after study 
enrollment. While the follow-up assessments were con-
ducted at three and 6 months post-intervention, treatment 
initiation was measured only at 3 months to capture the 
importance of early treatment initiation, which is associated 
with better long-term outcomes [50, 51]. ART initiation was 
assessed using NHLS data, based on a measure of creatinine 
that was performed prior to initiation of tenofovir (part of 
the standard first-line ART regimen in South Africa). ART 
workup blood tests as recorded in NHLS have been pre-
viously validated as an accurate measure to impute dates 
of treatment initiation among South African PWH who are 
receiving public-sector HIV care [52]. All treatment initia-
tion was verified with prescription data and pill bottle visu-
alization, in which participants brought their medications to 
a visit with the Treatment Ambassador, to show them they 
had initiated treatment.
Survey Instrument
Survey measures were administered at baseline and fol-
low-up to assess psychosocial characteristics, as well as 
sociodemographic and medical characteristics potentially 
related to behavior at baseline and at follow-up in both 
arms of the study to evaluate the moderators and media-
tors of intervention effects (see Table 2). The TTI states 
that health related behaviors are shaped by individual-, 
social-, and structural-level factors and thus, the survey 
attempted to analyze barriers at these three levels. Indi-
vidual-level factors included self-perceived health and 
wellness, as well as coping and mental health. These fac-
tors were measured using the Short Form-8 questionnaire 
to capture general health perceptions, the AUDIT scale 
to measure alcohol and recreational drug use, the Brief 
COPE to assess how participants deal with stressors, and 
the Patient Health Questionnaire to measure depression, 
anxiety, and somatic complaints [53–58]. The social-level 
factors included were perceived social support, measured 
using the Medical Outcomes Study Social Support Survey, 
HIV-associated stigma (internalized, enacted, and antici-
pated), measured using the Internalized AIDS-Related 
Stigma Scale and the HIV stigma framework, and disclo-
sure concerns, measured using HIV stigma scale [59–62]. 
Structural-factors included barriers to accessing ART and 
trust in ART efficacy, measured by assessing competing 
needs and barriers to care in the past 6 months and a scale 
Table 2  Behavioral survey measures
Individual-level factors
Attitudes and beliefs Self-perceived health and wellness
(1) General health perceptions were measured using the Short Form-8 questionnaire, which indicated personal 
ratings of health status, and how physical health problems affected usual activities and mood (0.87) [53, 54]
(2) A modified AUDIT scale was used to measure alcohol and recreational drug use (frequency of use of alcohol 
and a variety of other substances (α = 0.88) [55]
Capabilities Coping and mental health
(1) Brief COPE was used to assess for differences in how participants cope with stressors, including how often 
people engage in certain behaviors post-diagnosis of HIV, including denial, self-blame, substance use, behavio-
ral disengagement, self-distraction, and venting (15-items; (α = 0.86) [56, 57]
(2) Depression and anxiety symptoms and somatic complaints were measured using the 9-item Patient Health 
Questionnaire (PHQ) (α = 0.76) [58]
Social-level factors
Social interaction processes Perceived Social Support: Medical Outcomes Study (MOS) Social Support Survey (α for all subscales greater than 
0.91) [59]
HIV-associated internalized, enacted, and anticipated stigma: Internalized stigma was measured using the Inter-
nalized AIDS-Related Stigma Scale (α = 0.75) [60] Enacted and anticipated stigma (α between 0.87–0.89 for all 
subscales) was measured using the HIV stigma framework [61]
Disclosure concerns: Concerns were measured with a psychometric assessment of the HIV stigma scale (α = 0.96) 
[62]
Structural-level factors
Barriers to Accessing ART Barriers and competing needs were assessed by asking participants whether they had experienced each of 13 
problems when medical care was needed in the past 6 months (e.g. not knowing where to find care, affordabil-
ity of medications or transportation) [63] The count of each participant’s “yes” responses to these 13 yes/no 
items was taken as their score
Perceived quality of Care Trust in ART efficacy: Scale based on the RAND HIV Cost and Services Utilization Study (HCSUS) (Cronbach’s 
α = 0.71) [64, 65]
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based on the RAND HIV Cost and Services Utilization 
Study, respectively [63–65].
Intervention and  Assessment Feasibility: Study Participant 
Tracking Records and Fidelity Ratings Assessment of inter-
vention feasibility measures included participation with-
drawal and retention rates for the intervention and study 
assessments. We used the following benchmarks to assess 
feasibility of the intervention: ≤ 10% withdrawing from 
the intervention arm, ≥ 50% enrollment of eligible partici-
pants, ≥ 80% completion of 3-month and 6-month outcome 
assessments [66]. Sessions were recorded and scored to 
assess Treatment Ambassador’s fidelity to the intervention 
content and MI style using established procedures [40, 67, 
68]. Trained independent isiXhosa raters coded the extent to 
which Treatment Ambassadors addressed key session con-
tent as presented in the manual and training. Fidelity to key 
content delivery was measured using a checklist, rated as 
“yes” (1), “no” (0), “partially” (0.5), or “N/A” (excluded). 
Scores for each content item were summed to create a total 
score for each session. The overall average content fidel-
ity for all sessions was then calculated by averaging all the 
individual total session scores, with a 1 indicating perfect 
fidelity to the manualized session content. Fidelity to the 
MI strategies presented in the manual and training (i.e., 
reflective listening, asking permission, open ended ques-
tion, expressing empathy, summaries, and overall quality) 
was assessed using a modified version of the Motivational 
Interviewing Treatment Integrity (MITI) Code [22] which 
is scored on a 7 point scale. An overall average of 5 and 
above indicates excellent adherence to MI style throughout 
sessions.
Intervention Acceptability: Qualitative Data Semi-struc-
tured exit interviews were performed after completion of 
the intervention with a random subset of 30 participants (25 
intervention, 5 control; 100% Black African; 96% females). 
While the focus of these semi-structured interviews was to 
understand the acceptability of the intervention, we also 
chose to interview a small number of control participants to 
provide a comparison to intervention participants to under-
stand perceived barriers to and facilitators of ART initia-
tion in the absence of the intervention [29]. Interviews were 
conducted in isiXhosa or English, at participant’s preference 
and audio-recorded, transcribed, and translated as required. 
Qualitative data were entered into NVivo  10© (QSR Interna-
tional Pty Ltd 2014) software.
Data Analysis
Data analysis focused on characterizing perceived accept-
ability (extent to which people receiving an intervention 
consider it to be appropriate), which was operationalized in 
terms of attitudes toward and perceptions of the intervention 
and its components [23]. Sample questions to assess per-
ceived acceptability included questions regarding the struc-
ture of the sessions, comfort with the Treatment Ambas-
sador, cultural sensitivity, and the content and length of the 
survey. Using an inductive approach based upon grounded 
theory, categories were constructed to name, define, and 
illustrate content themes [69]. We searched interview data 
for key concepts that pertained to intervention acceptability 
and displayed the text in matrices to identify patterns. Pat-
terns of content appearing repeatedly in the data formed the 
basis for thematic categories. Coding began with a provi-
sional start-list of themes based on prior research. Twenty 
percent of the interviews (n = 6) were independently read 
and new themes were iteratively generated based on iden-
tifying themes that were not present in the start-list, which 
resulted in a codebook. The team members coded 20% addi-
tional interviews (n = 6) to calibrate the methods of evalu-
ation, and one individual, using the standards established, 
coded the remaining interviews (Cohen’s Kappa = 0.82). For 
each of the seven survey measures, we compared responses 
at 6 months by computing the mean response for each arm, 
a 95% bootstrap confidence interval for the between-arm 
difference in means, and a permutation test p-value for the 
between-arm difference in means adjusted for each partici-
pant’s baseline score. To assess preliminary efficacy, rates of 
ART initiation at 3 months for the two arms were compared 
by computing the relative “risk” of initiation and testing for 




At enrollment (Table 3), participants’ median age was 34 
(IQR 29, 43) years. Over three-quarters of the participants 
were female, and the majority were unemployed (88% in the 
control arm and 98% in the intervention arm). The median 
time since taking a diagnostic HIV-test was 33 (IQR 21, 53) 
months. Over half of the participants reported testing last for 
HIV due to “feeling sick” (51% in the control arm and 54% 
in the intervention arm). Across both arms, participants’ 
self-perception of health was good, very good, or excellent 
in the month prior to the intervention (86% in the control 
arm and 90% in the intervention arm); however, participants 
indicated challenges with coping (median 1 on a scale of 1 
to 4), and over 90% reported food insecurity. There were no 
statistically significant differences at baseline between those 
assigned to the intervention and control arms on psychoso-
cial, sociodemographic, and medical characteristics.
1136 AIDS and Behavior (2021) 25:1129–1143
1 3
Feasibility and Fidelity
The intervention was highly feasible, with 90% of the 41 par-
ticipants randomized to the intervention arm participating in 
the full intervention (three voluntarily withdrew before the 
intervention started and one voluntarily withdrew prior to 
completing the intervention). All 38 participants who started 
the intervention completed both the 3 and 6-month follow-
up surveys. There were no adverse or unintended effects 
reported during the intervention or follow-up assessments.
The intervention counselors maintained high levels of 
fidelity. All eight sessions delivered to the 38 interven-
tion participants who completed the full intervention were 
recorded, totaling in 256 recorded MI sessions. Roughly 
25% were chosen at random to assess session content and 
MI style fidelity. Of 73 sessions (29%) randomly selected 
to assess content fidelity, the median score was 0.90 (IQR 
0.81–0.95), with a score of 1 indicating that all content 
described in the manual was delivered in the session. Of 
71 sessions (28%) randomly selected to assess MI style, the 
median intervention session score was 4.3 (IQR 3.6–5.0) 
indicating strong use of MI strategies during counseling 
sessions.
Intervention Acceptability—Qualitative Data
The exit interview data indicated that all 25 intervention 
participants interviewed found the intervention to be highly 
acceptable. Acceptability clustered around five primary 
themes: (1) support from an “ideal” partner promoting self-
reflection; (2) support of autonomy and intrinsic motivation 
while promoting disclosure; (3) assistance with navigating a 
challenging clinical environment; and (4) the need to unpack 
barriers, including myths and misinformation, anticipated 
and internalized stigma, and denial. Table 4 summarizes 
results from our qualitative interviews. Individuals who 
engaged in the intervention but did not start ART reported 
several barriers to ART initiation that were not addressed by 
the intervention, including: structural challenges getting to 
clinic and waiting to be seen; competing needs and priori-
ties; and social isolation Suggestions to improve the inter-
vention from participants included: direct delivery of ART 
by nurses outside of a clinic setting; strategies to improve 
self-efficacy; and ongoing education regarding safety of 
ART usage (especially if using alcohol). See Table 5.
Survey Results
There was little evidence of difference between arms at 
6 months on the survey measures, including ARV efficacy, 
social support, internal stigma, disclosure concern, and bar-
riers (see Table 6). The exception was the depression meas-
ure (PHQ9). On average, intervention participants reported 
better (lower) scores (mean 0.32, SD 0.24) than control par-
ticipants (mean 0.61, SD 0.56) (95% CI for difference in 
Table 3  Socio-demographic and health characteristics at baseline
Control (n = 43) 
(Median, IQR)
Intervention (n = 41)
(Median, IQR)
Total (n = 84)
(Median, IQR)
Age at screening 34 (30, 43) 34 (27,43) 34 (29, 43)
Months since dx test 43 (23, 62) 30 (21, 48) 33 (21, 53)
Number of times participant tested for HIV 2 (1, 3) 2 (2, 3) 1 (1, 2)
CD4 at last HIV test 400 (340, 555) 460 (378, 546) 410 (375, 555)
Female 77% 88% 82%
Parent 86% 71% 79%
Employed 12% 2% 7%
Completed high school 93% 98% 95%
Most common reason for last HIV test 51% felt sick 54% felt sick 53% felt sick
Most common reason for not starting ART 45% not ready 44% not ready 45% not ready
Perceived general health
 Overall rating of health as good, very good, or excellent in past 4 weeks 86% 90% 88%
Substance use
 Drink alcohol four or more times per week 14% 22% 18%
 Ever smoke cigarettes 42% 63% 51%
 Ever used other recreational drugs 12% 12% 12%
Coping (ability to cope) 2-item scale (min 1, max 4) 1 (1, 1) 1 (1, 1) 1 (1, 1)
Belief in ARV efficacy 8-item scale (min 1, max 4) 3 (2.9, 3) 3 (3, 3) 3 (2.9, 3)
Most common reason to go without healthcare, money needed for… 93% food 90% food 92% food
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Table 4  Acceptability of the Treatment Ambassador Program–mechanisms of action (n = 25)
Support from an ideal partner Quote from participant
Gaining medical knowledge through the Treatment 
Ambassador Program
Well, sisi, they were not long, they were not short – [as] we were benefitting, getting 
educated. Being educated about things that are happening here in – in our bodies and 
in our journey. Because I wasn’t the kind of person who would use a condom. But now 
I’ve learned a lot. I am using the condom.
Social support
 Social support from family or friends The person that I have already informed, the first one is my boyfriend, my life partner. He 
knows. He once said to me, as I’m about to go to the clinic on the first week of Decem-
ber, ‘I can go with you, if they didn’t call me to work – [then] I will go with you to the 
thingamajig.’ [Thanks] to you. So, [thanks] to you guys, actually.
 Social support from TAP [The Treatment Ambassador] was telling me himself – about himself too, understand? 
So, he told that I should not be worried, I should be free. Well, I then became free as 
well – if he can tell me about – about his [HIV] status, so, perhaps I can be able to chat 
with him – about mine.
Support of autonomy and intrinsic motivation Quote from participant
Intrinsic motivation There’s nothing that people are going to do for you. You have to live for your children, 
that’s all – and for your family.
Self-efficacy The study, it has helped me – the first thing that I can tell you. It’s got me out of prob-
lems. Even that issue of sleeplessness – I do sleep now. Because I didn’t know who I 
am. I don’t want to lie, sisi. I didn’t know whether, who am I? Even if I’m worried, I 
throw everything on this problem that I’m in. But it is not a problem – It [used] to be a 
big problem. Now I am saying – today, since I’m attending the study, ‘It isn’t a problem. 
I am human, you know. I am alive.’
Disclosure It’s my boyfriend. [I previously worried] what’s he going to be like? But, man, I just 
became free, then I told him. He said he had been afraid to tell me himself first, for a 
long [time].
Assistance with navigating a challenging clinical 
environment
Quote from participant
Challenges with the clinic
 Challenges with patient/provider communication Interviewer: Which session did you [guys] perhaps discuss in, whereby you felt that you 
were becoming comfortable?
Participant: I can say, session – the session – the session – I think, the session about going 
to the clinic. You see? At the clinic, how to – perhaps going to the reception and enquir-
ing; how to handle the nurses. Yes. So, I would say, if the nurses ridicule you, you go to 
the superior, you see? Yeah, I would – I would say so.
Interviewer: So, how did you feel about that discussion then?
Participant: Yeah, ok, in that discussion I left with the information that I didn’t have. You 
see? Yeah. I am someone who likes going to the clinic. So, I left with the information 
that I didn’t have [before]. So, I a learnt a lot about the right thing.
 Challenges with Disclosure due to Clinic Structure The reason I was not able to go to take the treatment is because they will be talking about 
me. Because if you are there at the the Day Hospital, they watch which door you’re at. 
You find that in this queue, at this door, someone who lives with you gets to see you. 
He/she gets to the township and says, ‘Well, so-and-so is also like this. I saw her at a 
certain door.’
Unpacking persistent barriers Quote from participant
Myths and misinformation In starting the treatment, I used to be afraid because I saw it from my cousin, that it is bad. 
It made pimples appear on her – and a rash on her body. She became itchy, it left black 
spots on her. That’s why I was afraid in the beginning. But [the Treatment Ambassador] 
taught me that, no, it depends on the body’s parts, whether what are they like inside. But 
now that fear has left me.
Stigma
 Anticipated stigma I: So, when you say that, perhaps is it the way – How were you feeling in the past?
P: I used to think – I didn’t see myself being – being able to – I didn’t consider myself 
human among [other] humans.
I: What was causing that?
P: The guilty conscience I had about myself. It’s how I [felt] about myself.
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means = − 0.48, − 0.09; permutation test p-value, controlling 
for baseline scores = 0.002).
Preliminary Efficacy
Rates of confirmed ART initiation by 3 months in the inter-
vention and control arms were 12% (5/41) and 2% (1/43), 
respectively (Fisher exact p-value = 0.105; Cohen’s h = 0.41). 
Relative “risk” of ART initiation was 5.2 (95% CI 0.6–43.0). 
Rates of confirmed ART initiation by 3 months among those 
who were previously on ART in the intervention and control 
arms were 33% (5/15) and 14% (1/7), respectively (Fisher 
exact p-value = 0.616; Cohen’s h = 0.45, indicating a mean-
ingful effect size). Relative “risk” of ART initiation for this 
subgroup was 2.3 (95% CI 0.3–16.4). This exploratory study 
was not powered for definitive null hypothesis significance 
testing, but the first test of this new intervention was designed 
to explore preliminary efficacy.
Discussion
In this manuscript, we report on a novel behavioral 
intervention targeting a population at high-risk for poor 
health outcomes: PWH from a hard-to-reach population 
in South Africa who were aware of their status but were 
not taking ART nor engaged in care. These participants, 
all recruited though peers and other community members, 
were diagnosed with HIV on average 3 to 4 years prior to 
enrolling in the study. The Treatment Ambassador Pro-
gram was shown to be highly acceptable and feasible as a 
tool to improve initiation among a highly disenfranchised 
population. In addition, participants in the intervention 
arm reported improvements in symptoms of depression 
as compared to the control arm. Peers, whom we identi-
fied as Treatment Ambassadors, delivered the intervention 
with a high degree of fidelity, despite having no formal 
advanced degree or counseling training. Our promising 
findings demonstrate the potential for peer-delivered inter-
ventions and provide support for an approach that is both 
acceptable and feasible.
The use of peers as counselors is based on a substan-
tial literature that supports linking participants with peer 
supporters to promote HIV-related behavior change, with 
effect sizes generally comparable to provider-led inter-
ventions [24–26, 35, 70, 71]. Participants enrolled in the 
Treatment Ambassador Program cited gaining medical 
knowledge, social support, self-efficacy, support with 
disclosure, and overcoming challenges with stigmatizing 
health systems as critical aspects of the program. Among 
those initiating ART, intrinsic motivation, disclosing 
to a trusted friend or family-member, and an ability to 
overcome barriers appeared to be essential mechanisms 
of action. These findings are consistent with literature 
demonstrating that peer supporters can be credible role 
models and challenge negative peer norms about care and 
ART [27, 72–75]. Moreover, support with clinical naviga-
tion has been shown to improve engagement and retention 
of low-income PWH in HIV care [76], including in sub-
Saharan Africa [13, 28, 77]. This component was based 
on the Health Resources and Service Administration HIV 
System Navigation model [78], and informed by prior 
research in South Africa [79], focusing on a strengths-
based approach [80]. The individuals initiating ART in 
our sample described that the level of support provided 
by the Treatment Ambassadors was largely missing from 
their daily lives, supporting prior research that showed that 
Table 4  (continued)
Unpacking persistent barriers Quote from participant
 Internalized Stigma Back then I was afraid of – perhaps of – dis - discrimination, you see? Yes, I was afraid of 
that, getting judged. That perhaps I brought it upon myself; and it’s my fault – that I’m 
like this. Things like that – just some negative comments.
Denial At that time I heard some fear. I – I – I had thoughts that, no, probably they – they’ve 
made a mistake. You know? It – It – It can’t be inside me. It’s a disease that can perhaps 
happen to other people. You know. It’s not – I think I hadn’t accepted it yet or I hadn’t 
heard a lot – about it, I’d say so.
Hierarchy of needs The reason that now I still haven’t gone to the treatment – for, I am ready to take it – it’s 
just that I’m finishing writing [the exams] next Monday. So, after I’ve finished writing 
[the exams] next week, that’s when I’m going to just get up – Because I was stressed due 
to – it’s the study, on the [other hand] it’s the treatment, and then on the other it’s school, 
it requires – a lot from me. So, now that I’m going to finish writing, it’s only now that I 
am going to start the treatment – the treatment, I will get up – and go to the clinic.
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PWH struggle to trust family and friends due to concerns 
about stigma and discrimination [81].
Given that South Africa has the highest burden of HIV/
AIDS but a shortage of trained health care workers, task-
shifting and sharing of health service responsibilities are 
essential for a treatment model to be sustainable and scal-
able in this setting [27, 74, 75, 82]. Peer-delivered, com-
munity-based interventions, such as the Treatment Ambas-
sador Program, present both a scalable and sustainable 
solution to improving treatment for high-risk populations 
of PWH who struggle to engage in care. The feasibility 
and acceptability of this intervention suggest that there 
is untapped value in leveraging community resources 
to better engage these key populations. Peer interven-
tions have potential for high-impact in low resource set-
tings, as they reduce the burden on health care workers 
and strained health systems. Despite concerns that peer 
supporters could fail to deliver interventions with a high 
degree of fidelity, the Treatment Ambassadors in this study 
demonstrated that peers can be trusted to deliver interven-
tions and should be leveraged in settings with shortages 
of health care workers. While past studies have primarily 
evaluated the impact of interventions focused on improv-
ing ART adherence [39, 79] and engagement in HIV 
Table 5  Barriers to uptake and suggestions for the TAP Intervention
Theme Excerpt
Barriers
1 Structural challenges getting to 
clinic and waiting to be seen
“[Traveling to acquire medication] will still [cost] transport fare. The money won’t always be 
there, of course, for you to be travelling to take the pills. You see?” Female participant
2 Competing needs and priorities The reason that now I still haven’t gone to the treatment – for, I am ready to take it – it’s just 
that I’m finishing writing [the exams] next Monday. So, after I’ve finished writing [the 
exams] next week, that’s when I’m going to just get up – Because I was stressed due to – it’s 
the study, on the [other hand] it’s the treatment, and then on the other it’s school, it requires 
– a lot from me. So, now that I’m going to finish writing, it’s only now that I am going to 
start the treatment – the treatment, I will get up – and go to the clinic. Female participant
3 Social isolation among participants “… It’s fear of people. Like, you haven’t disclosed to your family; you haven’t disclosed to 
anyone else. Then if you are to go to the clinic, one of them is going to see you. So, then it 
is going to fill the community.” Female participant
Suggestions
1 Direct delivery of ART “I think the one that might be a good plan is that of people bringing [medication] to us..” 
Female participant
2 Promoting self-efficacy “Interviewer: We would like to make it bigger, so it’s good – as you are also praising it. What 
would you perhaps advise us to add, like, to this programme that we are conducting?
Participant: In this programme that I’m in, I wished that – as I also – as I was attending here, 
I do have some people whom I would like to get knowledge about this programme that you 
are doing, whom I could bring along, who don’t have knowledge. So, we can help them, 
so they can also be free. Because they are also affected the same way that I was affected.” 
Female participant
3 Ongoing education regarding 
safety of ART usage
“[I would like to learn] how you should live, in order to live a long life… And how you 
should ‘eat’ — you should ‘eat’ the treatment and the things that you perhaps see appearing 
on your [body], then advice — ask for advice; seek knowledge, perhaps.” Female partici-
pant
Table 6  Comparison of 
6-month scores for control and 
intervention participants
a 95% bootstrap confidence interval for difference between means
b Permutation test p-value for between-arm difference, controlling for baseline scores
Scale Control (n = 38) Intervention (n = 43) 95%  CIa for difference pb
Mean SD Mean SD
COPE (2 items) 1.53 0.85 1.24 0.57 − 0.59, 0.05 0.078
ARV efficacy 2.93 0.34 3.00 0.24 − 0.07, 0.19 0.356
Social support 4.22 0.64 4.39 0.65 − 0.10, 0.46 0.233
PHQ9 0.61 0.56 0.32 0.24 − 0.48, − 0.09 0.002
Internal stigma 2.61 1.50 2.30 1.26 − 0.92, 0.30 0.460
Disclosure concern 3.47 1.72 3.81 1.61 − 0.39, 1.02 0.221
Barriers 4.55 2.50 3.91 2.17 − 1.65, 0.39 0.405
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primary care [83, 84], or promoting early ART initiation 
within the context of “treatment for all,” [85] few behav-
ioral interventions have been designed for PWH who have 
delayed, declined, or discontinued ART [51].
This intervention showed high levels of feasibility and 
acceptability amongst a population that had remained out 
of treatment for, on average, 33 months since initial test-
ing. This demonstrates the promise of differentiated service 
delivery models in engaging populations who have delayed 
or declined ART for an extended period, especially highly 
disenfranchised populations such as the one identified in 
this study. This is consistent with previous research that has 
found that peer supporters have a unique ability to access 
hidden populations that may have limited interactions with 
the health care system [86]. Individuals in this population 
described persistent barriers to accessing care, such as struc-
tural challenges in getting to the clinic, competing needs 
and priorities, and social isolation. In the study population, 
individuals experienced high levels of food insecurity and 
reported that needing money for food was the most common 
reason to delay or decline health care. Given that food inse-
curity is commonly cited as a reason for poor clinic attend-
ance and poor ART uptake and adherence, it is important to 
address this competing need in order to improve adherence 
in this population [87]. While this intervention shows con-
siderable promise and potential in reaching these individu-
als, modifications to the intervention are needed for the next 
phase of this research program to address persistent barriers, 
and future studies with a longer follow-up period and a study 
of intervention mediators may shed light on whether the 
impact can be augmented.
Several key limitations in our study should be consid-
ered. First, this is an exploratory study with a modest sam-
ple size. Data on effects of psychosocial factors in the pilot 
study were generally inconclusive. For example, while 
participants who initiated ART reported disclosure to oth-
ers as a critical step to initiation, this sample was small 
and thus, these results do not necessarily imply that disclo-
sure is a necessary step in ART initiation. Studies with a 
larger population and a longer follow-up may provide more 
detail on specific mechanisms of action in this population. 
In addition, participants in our study were diagnosed with 
HIV for, on average, 3 years before enrolling. Prior data 
collected at this site show that the longer PWH wait from 
the point of testing to initiate ART, the less likely they are 
to ever engage in care [83]. These data are supported by 
other studies in sub-Saharan Africa [84, 85]. Therefore, 
the Treatment Ambassador Program has the potential to be 
more efficacious if offered closer to the time of HIV test-
ing. Further, participants highlighted persistent challenges 
with initiating treatment, such as structural challenges in 
getting to the clinic, competing needs and priorities, and 
social isolation, despite the acceptability and feasibility of 
this intervention. Future research is necessary that builds 
upon this intervention by incorporating the solutions to 
these barriers suggested by participants, such as direct 
delivery of ART, enhanced channels of social support, and 
ongoing education about the safety of ART usage.
Conclusions
There is an urgent need for interventions to improve rates 
of ART initiation among the 40% of South Africans living 
with HIV who are not on treatment. The present inter-
vention was found to be highly acceptable and feasible, 
providing a potential strategy to engage a highly disenfran-
chised population who are not traditionally represented 
in standard healthcare settings. The model presented here 
shows a promising pathway to harness the power of peers 
in delivering interventions, while maintaining a high 
degree of fidelity. Beyond this, it identifies several prom-
ising intervention components that merit further study.
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